Nippon Shinyaku said on June 21 that it has filed a new drug application in Japan for NS-87, a liposomal formulation of daunorubicin and cytarabine for injection, for the treatment of high-risk acute myeloid leukemia (AML). The company has developed…
To read the full story
Related Article
- Opdivo, Olumiant, Dupixent Now in Line for Label Expansions
February 6, 2024
- Label Expansion for Opdivo, Olumiant, Dupixent Up for PAFSC Review on Feb. 5
January 23, 2024
BUSINESS
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
- Nobelpharma Launches Pediatric Sleep Aid Melatonin in China
January 19, 2026
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





